Cart
sales@molnova.com
Lazertinib
CAS No. 1903008-80-9
Lazertinib( YH 25448 | YH25448 | GNS-1480 | GNS1480 )
Catalog No. M12983 CAS No. 1903008-80-9
Lazertinib (YH25448, GNS-1480) is a highly potent, mutant-selective, irreversible, brain-penetrant and orally active EGFR tyrosine-kinase inhibitors for both the T790M mutation and activating EGFR mutations.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 53 | In Stock |
|
| 5MG | 84 | In Stock |
|
| 10MG | 138 | In Stock |
|
| 25MG | 245 | In Stock |
|
| 50MG | 309 | In Stock |
|
| 100MG | 447 | In Stock |
|
| 500MG | 1035 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLazertinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionLazertinib (YH25448, GNS-1480) is a highly potent, mutant-selective, irreversible, brain-penetrant and orally active EGFR tyrosine-kinase inhibitors for both the T790M mutation and activating EGFR mutations.
-
DescriptionLazertinib (YH25448, GNS-1480) is a highly potent, mutant-selective, irreversible, brain-penetrant and orally active EGFR tyrosine-kinase inhibitors for both the T790M mutation and activating EGFR mutations; shows the beneficial for the NSCLC with brain metastasis.Lung Cancer Phase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsYH 25448 | YH25448 | GNS-1480 | GNS1480
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR (del19)|EGFR (T790M)|EGFR (T790M/L858R)
-
Research AreaCancer
-
IndicationLung Cancer
Chemical Information
-
CAS Number1903008-80-9
-
Formula Weight554.66
-
Molecular FormulaC30H34N8O3
-
Purity>98% (HPLC)
-
SolubilityEthanol: Insoluble; Water: Insoluble; DMSO: 10 mg/mL （ < 1 mg/ml refers to the product slightly soluble or insoluble )
-
SMILESC=CC(NC1=CC(NC2=NC=CC(N3N=C(C4=CC=CC=C4)C(CN(C)C)=C3)=N2)=C(OC)C=C1N5CCOCC5)=O
-
Chemical NameN-{5-[(4-{4-[(dimethylamino)methyl]-3-phenyl-1H-pyrazol-1-yl}pyrimidin-2-yl)amino]-4-methoxy-2-(morpholin-4-yl)phenyl}prop-2-enamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Patent US20160102076 A1.
2.?Yun J, et al. Clin Cancer Res. 2019 Jan 22. pii: clincanres.2906.2018. doi: 10.1158/1078-0432.CCR-18-2906.
molnova catalog
related products
-
Almonertinib mesylat...
Almonertinib mesylate is an irreversible inhibitor of EGFR tyrosine kinase with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate can be used in the non-small cell lung cancer studies.
-
JCN037
JCN037 is potent, non-covalent and brain-penetrant inhibitor of EGFR(EGFR, p-wtEGFR and pEGFRvⅢ with IC50 of 2.49 nM, 3.95 nM, 4.48 nM , respectively).
-
Epertinib
Epertinib (S-222611) is a novel potent, orally active, reversible EGFR and HER2 inhibitor with IC50 of 1.48, 7.15 and 2.49 nM for EGFR, HER2 and HER4, respectively.
